Skewed T-helper (Th)1/2- and Th17/T regulatorycell balances in patients with renal cell carcinoma

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 947-953

  Li, Long ^a   Yang, Cheng ^a   Zhao, Zitong ^a   Xu, Bin ^a   Zheng, Minghuan ^a   Zhang, Chao ^a   Min, Zhihui ^a   Guo, Jianming ^a   Rong, Ruiming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Regulatory T cells; Renal cell carcinoma; T helper cells

Indexed keywords

ADULT; AGED; FEMALE; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; MALE; MIDDLE AGED; MONONUCLEAR CELL; NORMAL HUMAN; REGULATORY T LYMPHOCYTE; TH1 TH2 BALANCE; TH17 CELL;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE; TH17 CELLS;

EID: 84916223932     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2778     Document Type: Article

References (31)

1. Figlin R, Sternberg C and Wood CG: Novel agents and approaches for advanced renal cell carcinoma. J Urol 188: 707-715, 2012.
2. Garcia JA and Rini BI: Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57: 112-125, 2007.
3. Finn OJ: Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res :36: 73-82, 2006.
4. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
5. Banerjee A, Vasanthakumar A and Grigoriadis G: Modulating T regulatory cells in cancer: how close are we? Immunol Cell Biol 91: 340-349, 2013.
6. Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell 133: 775-787, 2008.
7. Mougiakakos D, Choudhury A, Lladser A, Kiessling R and Johansson CC: Regulatory T cells in cancer. Adv Cancer Res 107: 57-117, 2010.
8. Cao X: Regulatory T cells and immune tolerance to tumors. Immunol Res 46: 79-93, 2010.
9. Zhou L, Chong MM and Littman DR: Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655, 2009.
10. Vojdani A: A potential link between environmental triggers and autoimmunity. Autoimmune Dis 2014: 437231, 2014.
11. Lang F, Linlin M, Ye T and Yuhai Z: Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder. J Clin Lab Anal 26: 365-371, 2012.
12. Gaur P, Qadir GA, Upadhyay S, Singh AK, Shukla NK and Das SN: Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr) 35: 335-343, 2012.
13. Bedke J1, Pritsch M, Buse S et al: Prognostic stratification of localized renal cell carcinoma by tumor size. J Urol 180: 62-67, 2008.
14. Edge SB, Byrd DR, Compton CC, et al (eds): Kidney. In: AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, pp479-89, 2010.
15. Al-Aynati M, Chen V, Salama S, et al: Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 127: 593-596, 2003.
16. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. Journal Histochem Cytochem 29: 577-580, 1981.
17. Ruffell B, DeNardo DG, Affara NI and Coussens LM: Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 21: 3-10, 2010.
18. Agarwal A, Agrawal U, Verma S, Mohanty NK and Saxena S: Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre-and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 32: 348-356, 2010.
19. Herber DL, Nagaraj S, Djeu JY and Gabrilovich DI: Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 67: 5067-5069, 2007.
20. Nishimura T, Iwakabe K, Sekimoto M, et al: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190: 617-627, 1999.
21. Ladoire S, Arnould L, Apetoh L, et al: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14: 2413-2420, 2008.
22. Wang J, Xu K, Wu J, et al: The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. BMC Cancer 12: 418, 2012.
23. Mizukami Y, Kono K, Kawaguchi Y, et al: Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 98: 148-153, 2008.
24. Liotta F, Gacci M, Frosali F, et al: Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 107: 1500-1506, 2011.
25. Svensson H, Olofsson V, Lundin S, et al: Accumulation of CCR4(+)CTLA-4 FOXP3(+)CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PloS One 7: e30695, 2012.
26. Chen KJ, Lin SZ, Zhou L, et al: Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PloS One 6: e24671, 2011.
27. Wilke CM, Bishop K, Fox D and Zou W: Deciphering the role of Th17 cells in human disease. Trends Immunol 2: 603-611, 2011.
28. Zamarron BF and Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7: 651-658, 2011.
29. Kryczek I, Wei S, Zou L, et al: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733, 2007.
30. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J and Wang RF: Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105: 15505-15510, 2008.
31. Sfanos KS, Bruno TC, Maris CH, et al: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14: 3254-3261, 2008.